



Changes to Board of Directors

San Diego, California and Sydney, Australia (Friday, 9 June 2017, AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) announces the changes to its board of directors that became effective at the 2017 Annual General Meeting of Stockholders (“Annual Meeting”), which was held 1 June 2017.

The Company’s Class I directors, consisting of two individuals elected to serve for a period of three years until their respective successors are elected and qualified, were up for election at the Annual Meeting. The Company’s Board unanimously nominated Brian H. Dovey, the Chairman of the Board and a continuing Class I director, for reelection and Ms. Regina Groves, the Company’s Chief Executive Officer who was previously not a director, for election at the Annual Meeting. Both individuals were elected by a plurality of the stockholder votes cast at the meeting and, therefore, Mr. Dovey continues as a Class I director and Ms. Groves joined as a Class I director effective 1 June 2017.

Ms. Anne Keating, the former Class I director whose term expired at the Annual Meeting previously notified the Company that she would not be submitting for reelection and would retire as a director on and from the Annual Meeting. Her retirement became effective at the Annual Meeting.

Commenting on the changes, Mr. Dovey said, “Anne has been a great asset to our Board, joining in 2010 prior to our Australian IPO. She brought a wealth of knowledge and experience to the Company and provided valuable guidance as we worked to bring our *Fantom* scaffold to market. We will miss her interaction, but are thankful for her years of service. With Anne’s retirement, we welcome Reggie to the Board and look forward to the continued commercial advancement of REVA.”

About REVA

REVA is a medical device company located in San Diego, California, USA, that has developed a proprietary bioresorbable scaffold, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s *Fantom*[®] scaffold has been designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact,

HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 • +1 (858) 966-3000 • +1 (858) 966-3099 (FAX) • www.revamedical.com

AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O’Connell Street, Sydney NSW 2000 • +61 2 9237 2800

ARBN 146 505 777 • REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to commercialize current products, develop and commercialize new products, timely and successfully complete clinical trials, obtain additional regulatory approvals, protect our intellectual property position, recruit and retain key personnel, and estimates regarding our capital requirements and financial performance. Readers should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on February 28, 2017 and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

United States**Investor & Media Enquiries:**

REVA Medical, Inc.
Cheryl Liberatore
Director, Communications
+1 858-966-3045

Australia**Investor Enquiries:**

Inteq Limited
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

Australia**Media Enquiries:**

Buchan Consulting
Rebecca Wilson
+61 3 9866 4722

HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 • +1 (858) 966-3000 • +1 (858) 966-3099 (FAX) • www.revamedical.com

AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O'Connell Street, Sydney NSW 2000 • +61 2 9237 2800

ARBN 146 505 777 • REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability
WEST277224999.1

For personal use only